CymaBay Therapeutics Inc

Most Recent

  • uploads///man _
    Company & Industry Overviews

    What’s Been Dragging Down CymaBay Therapeutics Stock

    CymaBay Therapeutics (CBAY) closed at $6.17 on June 12, 1.98% higher than its previous close, 28.01% above its 52-week low of $4.82, and 58.87% below its 52-week high of $15.

    By Margaret Patrick
  • uploads///medic _
    Healthcare

    CymaBay Rose 127% on Positive NASH Trial Update

    On Tuesday, CymaBay Therapeutics (NASDAQ:CBAY) stock rose 127.2% after the company highlighted a positive NASH trial update.

    By Ambrish Shah
  • Consumer

    Point72 Asset Management opens new position in Pier 1 Imports

    E-commerce represented approximately 1% of total sales in fiscal 2013, 4% in fiscal year 2014, 9% in the first quarter of fiscal 2015, and 9.7% in the second quarter of fiscal 2015.

    By Samantha Nielson
  • uploads///LL
    Consumer

    Point72 Asset Management raises stake in Lumber Liquidators

    The company “saw improvement in net sales trends over the course of the quarter as inventory levels recovered and the fall flooring season began.” But the shares are down 49% in the year to date.

    By Samantha Nielson
  • uploads///Cymabay
    Financials

    Point72 Asset Management takes position in CymaBay Therapeutics

    CymaBay Therapeutics is a clinical-stage biopharmaceutical company formerly known as Metabolex. It develops therapies to treat metabolic and rare diseases with high unmet need.

    By Samantha Nielson
  • uploads///AGTC
    Financials

    Point72 Asset Management adds position in Applied Genetic Tech

    Using the company’s partnerships and experience in ophthalmology, it plans to expand into a disease indication with a larger market. The company says it expects to place a new product candidate for this large market opportunity into development some time in 2015.

    By Samantha Nielson
  • uploads///stock _
    Company & Industry Overviews

    CymaBay Therapeutics: What Investors Should Watch For

    CymaBay Therapeutics (CBAY) is currently enrolling patients in its Phase 3 registrational trial, ENHANCE, to evaluate the use of its investigational PPARδ (peroxisome proliferator-activated receptor delta) agonist, seladelpar, in PBC (primary biliary cholangitis).

    By Margaret Patrick
  • uploads///graph _
    Company & Industry Overviews

    What Analysts Recommend for CBAY and VKTX

    This year, CymaBay Therapeutics (CBAY) has fallen 21.60% and Viking Therapeutics (VKTX) has risen 4.31%. While both clinical-stage companies focus on advancing their nonalcoholic steatohepatitis research and development programs, Viking seems to be ahead, considering its successful Phase 2 trials.

    By Margaret Patrick
  • uploads///thermometer _
    Company & Industry Overviews

    CymaBay Therapeutics Stock Crashes Over 50%: Is It Viable?

    June 11 turned out to be a terrible day for US biopharmaceutical company CymaBay Therapeutics’ (CBAY) investors.

    By Jitendra Parashar
  • uploads///joshua coleman  unsplash
    Company & Industry Overviews

    Why Achaogen Stock Fell Steeply Yesterday

    Yesterday, Achaogen (AKAO) announced that the FDA had approved its antibacterial agent, Zemdri (plazomicin), for adults suffering from complicated urinary tract infections (or cUTI) who don’t have significant treatment options.

    By Margaret Patrick
  • uploads///dna _
    Company & Industry Overviews

    How Analysts View BioMarin Pharmaceuticals and Peers in April

    Of the 23 analysts covering BioMarin Pharmaceuticals in April 2018, eight analysts gave the stock a “strong buy” rating.

    By Kenneth Smith
  • uploads///BMRN
    Company & Industry Overviews

    Cash Flows and Valuation Metrics of BioMarin Pharmaceuticals

    BioMarin Pharmaceuticals’ (BMRN) cash, cash equivalents, and investments increased from $1.3 billion in fiscal 2016 to $1.7 billion in fiscal 2017.

    By Kenneth Smith
  • uploads///CBAY
    Company & Industry Overviews

    Exploring CymaBay’s Other Promising Product Candidates

    CymaBay Therapeutics’ (CBAY) second product candidate, arhalofenate, is being developed for the treatment of gout.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.